Swiss drugmaker Roche is buying U.S.-based Jecure Therapeutics, joining Pfizer, Gilead Sciences and Novartis in pursuit of new drugs to treat fatty liver disease.
Roche did not say how much it was paying for Jecure, which gives it a preclinical portfolio of so-called NLRP3 inhibitors being developed for fighting inflammatory diseases like non-alcoholic steatohepatitis (NASH) and liver fibrosis as well as gout, inflammatory bowel disease and cardiovascular diseases.
Novartis and Pfizer last month teamed up to develop treatments for NASH, which many drug companies believe will become a hugely lucrative market, as it is tied to the obesity and diabetes epidemics. Unchecked, NASH can lead to advanced cirrhosis and liver failure.
“We’re excited to combine Jecure’s portfolio with our discovery and development capabilities, as well as our expertise in NLRP3 biology, to potentially help people with inflammatory diseases,” James Sabry, Roche’s head of partnering, said in a statement on Tuesday.
NASH, so far with no approved treatments, is poised to become the leading cause of liver transplants by 2020. [reut.rs/2HojtnT]
Jecure Therapeutics is focused on novel therapeutics for the treatment of NASH and liver fibrosis and was founded by Dr. Ariel Feldstein, who heads gastroenterology at the University of California San Diego School of Medicine.
By John Miller
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.